Controversies in mucosal healing in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 15, Issue 5, 2009, Pages 796-800

  Kane, Sunanda ^a   Lu, Frances ^b   Kornbluth, Asher ^b   Awais, Dahlia ^c   Higgins, Peter D R ^d  

^a MAYO CLINIC   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 23; MESALAZINE; STEROID;

CANCER RISK; CLINICAL TRIAL; COLON MUCOSA; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DYSPLASIA; ENDOSCOPY; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; RISK REDUCTION; ULCER HEALING; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; HUMANS; INTESTINAL MUCOSA; MUCOUS MEMBRANE; REGENERATION; WOUND HEALING;

EID: 67650305423     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20875     Document Type: Review

References (25)

1. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20.
2. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-2485.
3. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007;21:827-834.
4. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66-75; quiz 432-433.
5. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102.
6. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis [see Comment]. N Engl J Med. 2005;353:2462-2476 [erratum, N Engl J Med 2006;354:2200].
7. Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: preliminary results from a prospective, multicenter study. In: Association AG, ed. Digestive Disease Week. Chicago; 2006:A197.
8. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
9. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813-1816.
10. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099-1105.
11. Rubin D, Huo D, Rothe J, et al. Increased inflammatory activity is an independent risk factor for dysplasia and colorectal cancer in ulcerative colitis: a case-control analysis with blinded prospective pathology review. Digestive Disease Week. Gastroenterology; 2005:A103.
12. Rubin D, Huo D, Hetzel J, et al. Increased degree of histological inflammation predicts colectomy and hospitalization in patients with ulcerative colitis. Gastroenterology: Digestive Disease Week 2007:A103.
13. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461-465.
14. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431-436.
15. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786.
16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954;2:375-378.
17. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
19. Higgins PDR, Schwartz M, Mapili J, et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol. 2005;100:355-361.
20. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active procto-colitis. Scand J Gastroenterol. 1978;13:833-837.
21. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
22. Seo M, Okada M, Yao T, et al. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification. Am J Gastroenterol. 1995;90:1759-1763.
23. Manes G, Imbesi V, Ardizzone S, et al. Appropriateness and diagnostic yield of colonoscopy in the management of patients with ulcerative colitis: a prospective study in an open access endoscopy service. Inflamm Bowel Dis. 2008;14:1133-1138.
24. Su C, Lewis JD, Goldberg B, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516-526.
25. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459.